Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
Schizophrenia is one of the major psychiatric disorders for which effective pharmacotherapy has been available for approximately 50 years. Study of the mechanism of action of these antipsychotic drugs (APDs) has largely focused on the mesolimbic dopamine system and in the neurotransmitter systems that regulate it. Modulation of the neurotensin (NT) circuit in the mesolimbic system can underlie the mechanism of action of APDs. Several lines of evidence support this hypothesis, including: (1) association of NT with neural circuits relevant to the pathophysiology of schizophrenia and the therapeutic effects of APDs; (2) prediction of antipsychotic efficacy and side effect liability based on APD effects on the NT system; (3) low concentrations of NT in the cerebrospinal fluid of a subset of patients with schizophrenia and its normalization after associated clinical improvement with APDs; and (4) remarkable behavioral similarities between peripherally administered APDs and central NT administration. For these reasons, drugs that directly modify the activity of NT systems, particularly NT receptor agonists, could plausibly represent a novel class of APDs.
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
Ricardo
R
Cáceda
Becky
B
Kinkead
Charles B
CB
Nemeroff
D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D009415:Nerve Net / Q000187:drug effects / Q000378:metabolism; D018028:Receptors, Neurotensin / Q000187:drug effects* / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D018028:Receptors, Neurotensin; D004298:Dopamine